^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MB12 (pembrolizumab biosimilar)

    i
    Other names: MB12, MB-12, MB 12
    Associations

    News

    Trials
    Company:
    Insud Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) (clinicaltrials.gov)
    P3, N=726, Not yet recruiting, mAbxience Research S.L.
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • MB12 (pembrolizumab biosimilar)
    4ms
    MB12-C-01-22: Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov)
    P3, N=174, Recruiting, Laboratorio Elea Phoenix S.A. | Trial completion date: Dec 2025 --> Dec 2024 | Trial primary completion date: Aug 2025 --> Aug 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MB12 (pembrolizumab biosimilar)
    1year
    Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov)
    P3, N=174, Recruiting, Laboratorio Elea Phoenix S.A. | Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Mar 2023 --> Aug 2023 | Trial primary completion date: Mar 2025 --> Aug 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • MB12 (pembrolizumab biosimilar)
    almost2years
    Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC (clinicaltrials.gov)
    P3, N=174, Not yet recruiting, Laboratorio Elea Phoenix S.A.
    New P3 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • MB12 (pembrolizumab biosimilar)